HomeGBM • FRA
add
Inovio Pharmaceuticals, Inc.
Nakaraang pagsara
€3.80
Sakop ng araw
€3.85 - €3.85
Sakop ng taon
€3.69 - €12.14
Market cap
108.53M USD
Average na Volume
105.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 27.35M | 175.54% |
Net na kita | -25.17M | 25.83% |
Net profit margin | — | — |
Kita sa bawat share | -0.89 | 42.95% |
EBITDA | -26.93M | -10.37% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 84.80M | -49.36% |
Kabuuang asset | 107.06M | -44.56% |
Kabuuang sagutin | 33.52M | -38.99% |
Kabuuang equity | 73.54M | — |
Natitirang share | 26.10M | — |
Presyo para makapag-book | 1.35 | — |
Return on assets | -56.77% | — |
Return on capital | -69.87% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -25.17M | 25.83% |
Cash mula sa mga operasyon | -27.44M | 5.73% |
Cash mula sa pag-invest | 14.08M | 356.25% |
Cash mula sa financing | 660.65K | -5.44% |
Net change in cash | -12.70M | 62.53% |
Malayang cash flow | -17.47M | 10.73% |
Tungkol
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
Itinatag
1999
Website
Mga Empleyado
127
